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ABSTRACT
Introduction: Bloodstream infection (BSI) due to
extended-spectrum β-lactamase-producing Gram-
negative bacilli (ESBL-GNB) is increasing at an
alarming pace worldwide. Although β-lactam/β-
lactamase inhibitor (BLBLI) combinations have been
suggested as an alternative to carbapenems for the
treatment of BSI due to these resistant organisms in
the general population, their usefulness for the
treatment of BSI due to ESBL-GNB in haematological
patients with neutropaenia is yet to be elucidated. The
aim of the BICAR study is to compare the efficacy of
BLBLI combinations with that of carbapenems for the
treatment of BSI due to an ESBL-GNB in this
population.
Methods and analysis: A multinational, multicentre,
observational retrospective study. Episodes of BSI due
to ESBL-GNB occurring in haematological patients and
haematopoietic stem cell transplant recipients with
neutropaenia from 1 January 2006 to 31 March 2015
will be analysed. The primary end point will be case-
fatality rate within 30 days of onset of BSI. The
secondary end points will be 7-day and 14-day case-
fatality rates, microbiological failure, colonisation/
infection by resistant bacteria, superinfection, intensive
care unit admission and development of adverse events.
Sample size: The number of expected episodes of BSI
due to ESBL-GNB in the participant centres will be 260
with a ratio of control to experimental participants of 2.
Ethics and dissemination: The protocol of the
study was approved at the first site by the Research
Ethics Committee (REC) of Hospital Universitari de
Bellvitge. Approval will be also sought from all relevant
RECs. Any formal presentation or publication of data
from this study will be considered as a joint
publication by the participating investigators and will
follow the recommendations of the International
Committee of Medical Journal Editors (ICMJE). The
study has been endorsed by the European Study Group
for Bloodstream Infection and Sepsis (ESGBIS) and the
European Study Group for Infections in Compromised
Hosts (ESGICH).
Strengths and limitations of this study
▪ The multicentric design of the study will allow
the recording of a large number of episodes.
▪ The impact of therapy on mortality and other
relevant outcomes will be assessed.
▪ Owing to the retrospective design of the study,
some information may be lost.
▪ We may not be able to control for some mea-
sured and unmeasured confounders.
▪ Enrolling a sufficient number of patients treated
with β-lactam/β-lactamase inhibitor combinations
may be difficult.
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INTRODUCTION
The recent spread of extended-spectrum β-lactamases
(ESBLs) in Enterobacteriaceae has become a serious
public health problem worldwide.1 2 Bloodstream infec-
tion (BSI) due to these multidrug-resistant (MDR)
microorganisms is increasingly recognised among
patients with haematological malignancies and in haem-
atological stem cell transplant (HSCT) recipients, who
in addition, present an increased risk of severe sepsis
and death.3–6
Until recently, carbapenems, which are not affected by
ESBLs, were considered the drugs of choice for treating
severe infections caused by ESBL producers.1 2 For this
reason, while clinicians await new antimicrobials with
activity against these MDR microorganisms, they have
often been forced to use carbapenems as empiric or
deﬁnitive therapy in patients with suspected or docu-
mented infections due to an ESBL-producing organism.
However, the increasing use of carbapenems is particu-
larly worrisome in a scenario in which carbapenemase-
producing organisms are also emerging as a serious
health problem.7 8 Thus, the search for alternatives to
carbapenems for infections caused by ESBL producers is
a priority. Although ESBL-producing bacteria may also
have different resistance mechanisms that restrict the
activity of β-lactam/β-lactamase inhibitor (BLBLI) com-
binations, some of these agents remain active against a
considerable proportion of ESBL-producing enterobac-
teria, particularly Escherichia coli.9 10
Recent investigations, including two systematic reviews,
suggest that the combination of a BLBLI may be a reli-
able option for the treatment of BSI due to
ESBL-producing Gram-negative bacilli (ESBL-GNB),
especially in non-immunocompromised patients.11–16
Conversely, other studies have found higher mortality
rates in patients with BSI due to ESBL-GNB who
received piperacillin-tazobactam (PTZ) compared with
those treated with carbapenems.17–19 The impact of the
minimum inhibitory concentration (MIC) of PTZ on
outcomes of patients with these severe infections who
receive this regimen has also been questioned.19 20
Until now, the efﬁcacy and safety of BLBLI combina-
tions for the treatment of BSI due to ESBL-GNB in
HSCT recipients and haematological patients with neu-
tropaenia has not been elucidated. These patients are
particularly prone to develop life-threatening infections
and frequently receive broad-spectrum antibiotics.
This study aims to evaluate if BLBLI combinations are
as effective as carbapenems for the treatment of
ESBL-GNB BSI in this high-risk population.
OBJECTIVES OF THE STUDY
Primary end point
To compare the efﬁcacy of BLBLI combinations with
that of carbapenems for the treatment of BSI due to
ESBL-GNB in haematological patients with neutropae-
nia, in terms of a 30-day case-fatality rate.
Secondary end points
To compare the rates of the following events in these
two groups of patients:
1. Seven-day and 14-day case-fatality rates.
2. Microbiological failure, deﬁned as the presence of at
least one of the following criteria:
A. Persistent BSI beyond the ﬁrst 48 hours of
adequate antibiotic therapy.
B. Relapse of BSI within 7 days of treatment
discontinuation.
3. Colonisation/infection by bacteria resistant to the
study antibiotics.
4. Any bacterial superinfection other than ESBL-GNB.
5. Intensive care unit admission.
6. Development of adverse events:
A. Any adverse event.
B. Adverse events requiring treatment
discontinuation.
METHODS AND ANALYSIS
Study design
A multinational, multicentre, retrospective, observational
cohort study involving the collection of data of patients
from 1 January 2006 to 31 March 2015.
The study will be conducted in accordance with the
STROBE recommendations.21
Study population
Data will be collected on haematological patients with
neutropaenia with at least one episode of BSI due to an
ESBL-producing Enterobacteriaceae and who receive carba-
penems or BLBLI combinations as the empirical or
deﬁnitive antibiotic therapy.
Setting
The study will be conducted at 22 centres from nine dif-
ferent countries: Spain (11 centres), Brazil (3 centres),
Argentina (2 centres), Australia (1 centre), Canada
(1 centre), Germany (1 centre), Italy (1 centre), Turkey
(1 centre) and the USA (1 centre). The great majority
of participating centres (20) are university hospitals,
except for Hospital Rawson in San Juan, Argentina and
Barcelona Hospital in Barcelona, Spain.
Selection of cases
Patients will be identiﬁed from previous prospective
databases or from the records of the microbiology
laboratory of each hospital.
Inclusion criteria
1. Adult patients (≥18 years).
2. Patients with haematological diseases and/or HSCT
recipients, both autologous and allogeneic.
3. The presence of neutropaenia (<500 neutrophils/
mm3) at onset of the episode of BSI.
4. Episodes of monomicrobial BSI due to any species
of ESBL-producing Enterobacteriaceae, including
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community, healthcare and nosocomial infections.
ESBL production would have been screened in all
isolates with diminished susceptibility to cephalospor-
ins and conﬁrmed according to standard procedures.
The ESBLs would have been identiﬁed by using
phenotypic or molecular methods, when needed.
5. Antibiotic therapy with a BLBLI combination or a car-
bapenem for at least 24 hours. A 24-hour course of
antibiotics might not be enough to optimally evaluate
its impact on outcomes. However, since carbapenems
have been the recommended treatment for serious
ESBL infections, it could be very difﬁcult to collect
patients who have received a long course of BLBLI
therapy. Moreover, the empirical antibiotic therapy
administered to a high-risk neutropaenic patient with
Gram-negative BSI within the ﬁrst 24 hours has prob-
ably the highest impact on outcome.
6. Subsequent episodes in a patient caused by the same
organism may be included if the interval between
them is >1 month.
Exclusion criteria
Patients with any of the following will be excluded from
the study:
1. Episodes of polymicrobial BSI.
2. Unavailability of key data (data regarding empirical
and targeted therapy and mortality).
3. Episode occurring outside the study period.
4. Age <18 years.
Data collection
Patients’ data will be collected retrospectively. These
data will be obtained from various sources, including
patients’ electronic records, patients’ notes, the hospital
laboratory systems and the hospital patient administra-
tion system.
The following data will be collected for all cases: sex,
age, underlying disease and comorbidities, haemato-
logical malignancy status, severity of the episode of
febrile neutropaenia according to the Multinational
Association of Supportive Care in Cancer (MASCC)
index score,22 place of acquisition of infection,23 source
of BSI, BSI source control status, clinical and microbio-
logical data, duration of neutropaenia, prior therapies
received (antibiotics, immunosuppressors, etc), empir-
ical and deﬁnitive antimicrobial therapy, reason for
change of antimicrobial therapy, duration of each anti-
biotic therapy, need for intensive care unit admission
and mechanical ventilation, persistent BSI, relapse of
BSI, colonisation and/or superinfection by resistant
organisms, development of other complications, 7-day
case-fatality rate, 14-day case-fatality rate, 30-day case-
fatality rate, and development of adverse events.
Definitions
▸ Antimicrobial therapy administered before suscepti-
bility results were available will be considered as
empirical therapy, and antibiotic therapy adminis-
tered afterwards will be considered as deﬁnitive.
▸ Therapy with a BLBLI combination or a carbapenem
will be considered as monotherapy if no other drug
with activity against Gram-negatives was co-adminis-
tered, irrespective of the isolate susceptibility.
▸ Adverse events will include any of the following events:
moderate or severe allergic reactions, severe renal
impairment, severe liver impairment and seizures.
Participant timeline
The follow-up period will last 1 month after the onset of
BSI.
Study outcomes and end point assessment
Primary end point
▸ Case-fatality rate at 30 days from onset of BSI.
Secondary end points
▸ Seven-day and 14-day case-fatality rates from onset of
BSI.
▸ Time to death, in days.
▸ Microbiological failure, deﬁned by:
– Persistent BSI beyond the ﬁrst 48 hours of adequate
antibiotic therapy.
– Relapse of BSI within 7 days of treatment
discontinuation.
▸ Rate of colonisation/infection by bacteria resistant to
the study antibiotics.
▸ Rate of superinfection due to any bacteria.
▸ Rate of intensive care unit admission.
▸ Rates of adverse events including:
– Any adverse event.
– Adverse events requiring treatment discontinuation.
Sample size
The total number of episodes of BSI due to ESBL-GNB
in the participant centres during the study period will
determine the sample size. We expect an amount of 260
episodes with a ratio of control to experimental partici-
pants of 2. Prior data indicate that the 30-day case-
fatality rate among controls is 17%. Thus, with an α risk
of 0.05 and a β risk of 0.2 in a two-sided test, we will be
able to detect a true 30-day case-fatality rate of 5% or
32% in exposed participants. We will use an uncorrected
χ2 statistic to evaluate this null hypothesis.
Statistical analysis
Patients who were given BLBLI will be compared with
those who were treated with carbapenems empirically
and/or as deﬁnitive therapy.
Two non-mutually exclusive cohorts will be con-
structed and analysed separately. The empirical therapy
cohort (ETC) will include patients who received empir-
ical therapy with BLBLI or carbapenem, and the isolate
was susceptible to the empirical antimicrobial adminis-
tered. The deﬁnitive therapy cohort (DTC) will include
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patients who received deﬁnitive monotherapy with an
active BLBLI or carbapenem.
Continuous variables will be compared by means of
the Mann-Whitney U test and t-test. Qualitative variables
will be compared using the χ2 test, and relative risks and
95% CIs will be calculated.
We will use an uncorrected χ2 statistic to evaluate the
primary end point under the null hypothesis of a 30-day
case-fatality rate between study groups. Mortality survival
functions of patients treated with BLBLI or carbapenems
will be estimated using Kaplan-Meier curves and com-
pared using a log-rank test. Moreover, survival functions
will be compared also at days 7, 14 and 30 to detect very
early, early or late mortality differences. To control for
confounding, multivariate analysis will be performed by
the Cox proportional hazard model, using time until
death as the dependent variable and therapy with BLBLI
or carbapenem as the explanatory variable of interest. In
both cohorts (ETC and DTC), a propensity score for
receiving carbapenem as empirical therapy will be added
to the model. The propensity score—the probability of
receiving carbapenem as empirical and/or targeted
therapy—will be calculated using a non-parsimonious
multivariate logistic regression model in which the
outcome variable will be the use of carbapenem as
empirical therapy. Each patient will be matched to
another patient using the nearest participant matching
technique. The analysis will be performed with the step-
wise logistic regression model of R software (R V.3.2.5).
ETHICAL ISSUES
Prior to the initiation of the study at a particular site,
approval will be sought from all appropriate regulatory
agencies and the local Research Ethics Committees
(RECs) to conduct the study in accordance with the
local regulatory requirements. The study will only use
data routinely collected in the time frame January 2006
to March 2015. No extra tests or interventions will be
undertaken in patients and the study will have no
impact on patient care or outcome.
The processing of the patients’ personal data collected
in this study will comply with the European Directive on
Data Privacy. All data will be collected, stored and pro-
cessed anonymously (EU Directive 95/46/EC).24 All
data will be stored in a speciﬁc database.
The protocol (V2.0 15/5/2015) was approved on 21/
5/2015 by the REC at the ﬁrst site. The need for
informed consent and information sheets was waived by
the REC because of the retrospective nature of the study.
Publication plan
Results will be reported at conferences and in peer-
reviewed publications. The ﬁrst publication is based on
data from all sites, and is analysed as stipulated in the
protocol with supervision by statisticians. Any formal
presentation or publication of data collected from this
study will be considered as a joint publication by the
participating investigators and will follow the recommen-
dations of the International Committee of Medical
Journal Editors (ICMJE).
DISCUSSION
The emergence and dissemination of ESBL-GNB has
become a serious problem worldwide, and is especially
worrisome in immunosuppressed patients with cancer
and HSCT recipients, who are at risk of severe infection
and death.3–6
Until recently, carbapenems have been regarded as the
drugs of choice for the treatment of serious ESBL-GNB
infections such as BSI. They have been widely used for
the treatment of patients with suspected or documented
infections due to these organisms. However, their overuse
may induce the appearance of resistance to this
agent,25 26 thus severely limiting future treatment options.
This possibility is of particular concern in a scenario in
which carbapenemase-producing organisms are also
spreading and are adversely compromising patient’s out-
comes.26 27 Therefore, it is extremely important to iden-
tify therapeutic alternatives to these drugs.
The published data on the use of BLBLI combinations
for the treatment of infections caused by ESBL-GNB are
conﬂicting.11–19 In addition, different factors may be
involved in the outcomes of patients treated with these
drugs, such as type of infection, the ‘inoculum effect’ to
PTZ (ie, diminished activity with the presence of high
bacteria inoculum), the impact of the MIC of this drug
and the potential increase in efﬁcacy when using high
doses.19 20 28 Moreover, the existing literature includes
mainly non-immunocompromised patients, and informa-
tion is lacking regarding the usefulness of these agents
for the treatment of BSI due to ESBL-GNB in high-risk
haematological patients with neutropaenia, including
HSCT recipients.
The studies performed in the general population
addressing this issue usually carry methodological chal-
lenges, which may also be observed in the present
study.13–19 First, all reported studies are retrospective.13–19
Randomised controlled trials comparing empirical and
deﬁnitive antibiotic regimens are difﬁcult to perform in
this setting. Nevertheless, a randomised clinical trial is
being undertaken in several Australasian sites, including
Singapore (the ‘MERINO’ trial, registered at http://
www.clinicaltrials.gov; NCT02176122), and aims to be
completed by 2018. Second, most of the published
studies involve patients with BSI from the urinary tract,
and the results may not be generalisable to patients
with other sources of BSI.13–16 19 Third, the BLBLI
usually studied is PTZ and, less frequently, amoxicillin-
clavulanate; therefore, the results should not be
extended to other newer BLBLI currently being devel-
oped, until more data are available.13–19 Finally, informa-
tion regarding the MIC for PTZ,15–17 as well as the doses
used for each antibiotic, may not be available in all
studies.14 16 18
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This study aims to assess the efﬁcacy of BLBLI com-
binations in comparison with carbapenems for the
treatment of high-risk immunocompromised haemato-
logical patients with BSI due to ESBL-producing
Enterobacteriaceae. It is expected to provide important
information regarding the usefulness of BLIBLI com-
binations as carbapenem-sparing antibiotic regimens
for infections caused by ESBL-GNB, which represents a
key step in the efforts to minimise the spread of
carbapenem-resistant microorganisms. Information on
this issue will be particularly important in a population
prone to receive frequent, repeated cycles of broad-
spectrum antibiotics, and which often presents with
serious or life-threatening infections.
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